share_log

6-K: Jemperli (Dostarlimab) Trial Continues to Show Unprecedented Results with No Evidence of Disease in 100% of Patients with Locally Advanced Mismatch Repair Deficient (Dmmr) Rectal Cancer

6-K: Jemperli (Dostarlimab) Trial Continues to Show Unprecedented Results with No Evidence of Disease in 100% of Patients with Locally Advanced Mismatch Repair Deficient (Dmmr) Rectal Cancer

6-K:Jemperli (Dostarlimab) 试验继续显示出前所未有的结果,100% 局部晚期错配修复缺陷 (Dmmr) 直肠癌患者没有疾病证据
美股sec公告 ·  06/03 09:00
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息